Free tool
FAERS Monitor: Wainua (Autoinjector)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217388 or its brand name (Wainua (Autoinjector), Eplontersen Sodium). Reports on generic versions are filed under their own applications.
Reports
175
Serious
76
43% of reports
Hospitalization
21
Death reported
16
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death16
- fatigue13
- nausea13
- neuropathy peripheral13
- pain9
- product dose omission issue7
- vomiting7
- diarrhoea6
- hypoaesthesia6
- pain in extremity6
- paraesthesia6
- vision blurred6
- constipation5
- drug ineffective5
- pruritus5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 51 |
| 2025 | 102 |
| 2026 | 22 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,984 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuropathy peripheralSignal | 13 | 16.4 | 9.7 | 174 |
| vision blurredSignal | 6 | 5.3 | 2.4 | 17 |
| hypoaesthesiaSignal | 6 | 4.8 | 2.2 | 15 |
| product dose omission issueSignal | 7 | 2.9 | 1.4 | 7 |
| constipationSignal | 5 | 2.8 | 1.2 | 4 |
| pain in extremity | 6 | 2.4 | 1.1 | 4 |
| deathSignal | 16 | 2.2 | 1.4 | 10 |
| fatigueSignal | 13 | 2.0 | 1.2 | 6 |
| nausea | 13 | 2.0 | 1.2 | 6 |
| vomiting | 7 | 1.8 | 0.9 | 2 |
| pain | 9 | 1.8 | 0.9 | 2 |
| pruritus | 5 | 1.6 | 0.7 | 1 |
| diarrhoea | 6 | 1.1 | 0.5 | 0 |
| drug ineffective | 5 | 0.5 | 0.2 | 3 |
| paraesthesia | 6 | 0.0 | 0.0 | 606,555 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.